[HTML][HTML] Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500
JB Smerage, WE Barlow, GN Hortobagyi… - Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
JB Smerage, WE Barlow, GN Hortobagyi, EP Winer, B Leyland-Jones, G Srkalovic…
Journal of Clinical Oncology, 2014•ncbi.nlm.nih.govPurpose Increased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole
blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized
trial of patients with persistent increase in CTCs tested whether changing chemotherapy
after one cycle of first-line chemotherapy would improve the primary outcome of overall
survival (OS).
blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized
trial of patients with persistent increase in CTCs tested whether changing chemotherapy
after one cycle of first-line chemotherapy would improve the primary outcome of overall
survival (OS).
Abstract
Purpose
Increased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized trial of patients with persistent increase in CTCs tested whether changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcome of overall survival (OS).
ncbi.nlm.nih.gov